Tasigna 150 mg hard capsules
Sponsors
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Fondazione Gimema Franco Mandelli Onlus, Fondazione Gimema Franco Mandelli Onlus, Grupo Espanol De Leucemia Mieloide Cronica (GELMC), Masarykova Univerzita, Centre Hospitalier Universitaire De Poitiers
Conditions
Advanced solid tumorBCR-ABL1+ Chronic Myeloid LeukemiaCML-Patients in chronic phase having failed a prior attempt to stop imatinib or other TKIs therapy either within EURO-SKI or not and are pretreated at least one year with any TKI after 1st stopChronic Myeloid LeukemiaChronic Myeloid Leukemia (CML) in Chronic Phase (CP)Chronic myeloid leukemiaMultiple myelomaNon-Hodgkin lymphoma
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with nilotinib in first-line therapy followed by a second attempt after nilotinib and asciminib combination: DANTE study
CompletedCTIS2024-516122-66-00
Start: 2019-01-18End: 2025-10-15Target: 170Updated: 2025-07-09
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular Remission
Active, not recruitingCTIS2024-514592-17-00
Start: 2020-06-16Target: 221Updated: 2025-11-06
Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI 2nd or 3rd time
Not yet recruitingCTIS2024-519472-69-00
Target: 75Updated: 2024-11-27
Asciminib as single agent or in combination with nilotinib in the 1st-line treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a GIMEMA-GELMC phase II study. CML1624
RecruitingCTIS2024-512696-12-00
Start: 2025-06-24Target: 160Updated: 2025-11-17